Berent Lundeen, Ph.D.

Berent Lundeen, Ph.D., has a diverse and extensive work experience in the field of biology and research. Berent currently holds the position of Senior Scientist, Biology at Dunad Therapeutics since January 2023. Prior to this, they worked as a Scientist II at Faze Medicines from May 2022 to January 2023.

Before their current roles, Lundeen worked at Epizyme, where they held various positions. Berent was a Biological Scientist from August 2021 to May 2022, a Principal Research Associate from February 2020 to August 2021, and a Senior Research Associate from October 2017 to February 2020.

Lundeen's research journey began as a Ph.D. Researcher at Chomienne Lab, Université Paris VII Denis Diderot, Paris Sorbonne Cité, from September 2011 to December 2016.

Berent also has experience in education, having served as the Head of Science Education at Sylvan Learning Center of Darien from January 2009 to August 2011, where they provided tutoring to high school students in physics, chemistry, and biology.

Additionally, Lundeen has worked as a Research Assistant at Fred Hutchinson Cancer Research Center from May 2010 to August 2010, primarily focusing on myelodysplastic syndrome research. Berent also gained research experience as a Research Assistant at Johns Hopkins Medical Institutions from February 2007 to August 2008, working on the development of chimeric DNA vaccines for cancer and diseases.

Overall, Lundeen's work experience demonstrates their expertise in biology research, with a focus on oncology, genetic diseases, and vaccine development.

Berent Lundeen, Ph.D. holds a Doctor of Philosophy (Ph.D.) degree in Molecular Biology from Université Paris Cité, which was completed from 2011 to 2015. Prior to this, Lundeen obtained a Master's Degree in Medical Sciences from New York Medical College between 2009 and 2011. Earlier in their academic career, Lundeen earned a Bachelor's Degree in Molecular Biology from The Johns Hopkins University, spanning from 2005 to 2009.